Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

DBV Technologies (DBV) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Dbv712 250 McgAllergy, Peanut AllergyPhase IIIRecruitingSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)May 27, 2025
Dbv712Allergy, PeanutPhase IIIActive Not RecruitingSafety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgeFeb 14, 2023―
Dbv712 250 McgPeanut AllergyPhase IIICompletedFollow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young ChildrenFeb 19, 2019―
Part A Viaskin Peanut 250 Mcg, Part A Viaskin Peanut 100 Mcg, Part B Viaskin Peanut 250 McgPeanut AllergyPhase IIICompletedSafety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of AgeJul 05, 2017―
Viaskin Peanut 250McgPeanut AllergyPhase IIICompletedEfficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut AllergyNov 19, 2015―
Viaskin Milk 150 Mcg, Viaskin Milk 300 Mcg, Viaskin Milk 500 McgFood Allergyphase1AndPhase2CompletedEfficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk AllergyAug 20, 2014―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Dbv Technologies SA (UK) (FR:DBV) have in its pipeline
DBV Technologies FR:DBV is currently developing the following drugs: Dbv712 250 Mcg, Dbv712, Part A Viaskin Peanut 250 Mcg, Part A Viaskin Peanut 100 Mcg, Part B Viaskin Peanut 250 Mcg, Viaskin Peanut 250Mcg, Viaskin Milk 150 Mcg, Viaskin Milk 300 Mcg, Viaskin Milk 500 Mcg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.